• Thymoma
• Early lung cancer in specific groups
• Thromboembolic events in NSCLC
• Resistance to immune check point inhibitors
• Immunotherapy
• Combined treatment in stage III NSCLC
• Metastasis
• MSCLC: ALK mutation
• ASCO 2020